

Special Issue

Hematopoietic Stem Cell Transplantation in the Personalized Medicine Era

Message from the Guest Editors

Allogeneic hematopoietic stem cell transplantation (HSCT) can be curative for patients with severe hematological malignancies. Though the treatment modality has improved drastically over the last decade, e.g. tumor resistance, relapse, infections and Graft-versus-host-disease (GVHD) are still common challenges for these patients. The era of personalized medicine has dramatically changed the game plan for several diseases in the last decade including patients that undergo HSCT. Current advances in technology have provided scientists and physicians with a huge toolbox with possible instruments in order to improve the clinical outcome of these patients. This Special Issue of the *Journal of Personalized Medicine* aims to highlight the knowledge and illustrate some of the findings in HSCT. It will among other things include studies on the impact of donor characteristics and how pre-transplantation factors impact clinical outcome. It will also give examples of studies on the use of biomarkers to predict and govern clinical practise. Some examples will also illustrate how the use of tailor-made chemotherapy can be beneficial in patient care in a personalized setting.

Guest Editors

Prof. Dr. Michael Uhlin

1. Department of Clintec, Karolinska Institutet, SE-141 86 Stockholm, Sweden
2. Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, SE-141 86 Stockholm, Sweden

Prof. Dr. Moustapha Hassan

Division of Experimental Cancer Medicine (ECM), Department of Laboratory Medicine, Karolinska Institutet, SE-141 86 Stockholm, Sweden

Deadline for manuscript submissions

closed (31 December 2021)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/76273

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).